Details of the Drug
General Information of Drug (ID: DMEW3L0)
Drug Name |
N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid; N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE; 701223-63-4; DFW; 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]acetic acid; 2-({5,6-diphenylfuro[2,3-d]pyrimidin-4-yl}amino)acetic acid; 2brh; CBKinase1_018018; furanopyrimidine compound 4; CBKinase1_005618; AC1LI48C; SCHEMBL6748456; CHEMBL363302; BDBM14802; MolPort-002-125-656; ZINC383023; AKOS015957210; MCULE-9828982030; DB07653; L-3296; SR-01000273355; SR-01000273355-1; BRD-K42410867-001-01-6; F1684-0511
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 345.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||